Small Caps – Invex Therapeutics chases global registration of Presendin to treat idiopathic intracranial hypertension
Invex Therapeutics closes busy quarter of development on Presendin for idiopathic intracranial hypertension
Invex Therapeutics receives US FDA feedback on planned Presendin trial targeting idiopathic intracranial hypertension
Small Caps – Invex Therapeutics pushes on with phase three trial design to repurpose drug for brain disorder
